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osting by EAbstract Background and aim: The LMO2 gene encodes a transcription factor that regulates key
events in erythropoiesis, angiogenesis, and embryogenesis and is highly expressed at the most imma-
ture stages of lymphopoiesis. Its implication in Hodgkin lymphoma (HL), Burkitt lymphoma (BL)
and diffuse large B cell lymphoma (DLBCL) is limited in the literature.
Material and methods: An immunohistochemical study was performed on 68 lymphoma specimens
showing different types including Hodgkin lymphoma (23), Burkitt lymphoma (10) and diffuse
large B cell lymphoma (35). Also, seven specimens of the reactive nodal tissue were included as con-
trol. A monoclonal anti-human antibody has been used to detect LMO2.
Results: LMO2 was detected in all cases of HL (100%), in nine cases of BL (90%) and in all cases of
DLBCL of germinal center (GC) subtype 20/35 (57.1%) but is completely negative in non-
germinal center (NGC) DLBCL. In normal control of reactive nodes, LMO2 was expressed in germi-
nal center area but not expressed in other areas includingmantle,marginal, orT cell zones. InDLBCL;
therewas no statistically signiﬁcant relation betweenLMO2positive cases and the studied clinicopath-
ological parameters including patient’s age, sex and tumor site, stage and histological subtype. On the
other hand, it was statistically signiﬁcant regarding immunophenotyping of GC versus NGC.
Conclusions: LMO2 expression is a special feature of GC DLBCL which can be used as a diagnostic
marker and therapeutic target. Further studies regarding its prognostic role in patients are recom-
mended.
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148 T.M. ShamsIntroduction
In Egypt, lymphoma is considered as the fourth ranking adult
tumor, it represents (11.6%), 76.6% non-Hodgkin lymphoma
(NHL) and 23.4% Hodgkin lymphoma (HL). The clinically
aggressive subtypes such as diffuse large B-cell lymphoma
(DLBCL) and Burkitt lymphoma (BL) are the most frequent
diagnostic subtypes of non-Hodgkin lymphoma, representing
40–50% of all adult non-Hodgkin lymphomas [1]. In the Uni-
ted States the number of estimated new cases for lymphoma is
74,030 with an estimated cancer death of 21,530 [2].
Recently, gene expression proﬁling has been used to identify
prognostic subsets of DLBCL, with the germinal center B-cell
(GCB) DLBCL subgroup, demonstrating a superior 5-year sur-
vival compared with the activated B-cell (ABC) DLBCL sub-
group [3,4]. Because gene expression proﬁling is impractical
for routine clinical practice, a few studies have used the immuno-
histochemical expression of CD10, bcl-6, or MUM1 to classify
cases of DLBCL into GCB (CD10+ or CD10, BCL6+, and
MUM1) and non-GCB (CD10 and MUM1+) subgroups
[5–9]. However, the resulting data are conﬂicting, with 2 studies
showing a signiﬁcantly better survival for the GCB group [6,9]
whereas two others have found no difference in survival between
theGCBand non-GCBgroups [7,8]. Accordingly, the search for
novel diagnostically relevant markers and therapeutic targets
continues.
LMO2 is the Lim Domain. Only two genes encode a
cystein-rich LIM domain containing transcription factor that
is required for the complete hematopoiesis in mice [10] (it is
also termed RBTN2 and TTG2). While it was expressed in dif-
ferent tissues during fetal life its expression in hematopoietic
cells is tightly regulated and varies at different stages of matu-
ration. In normal B-cell differentiation and maturation, LMO2
is expressed mainly at two stages: at early lymphopoiesis with-
in the bone marrow and in germinal centers (GC) of secondary
lymphoid organs [11].
Expression of LMO2 has not been identiﬁed in a number of
different epithelial malignancies [11], to the best of our knowl-
edge, there is no published full length literature directly evalu-
ating its expression in DLBCL, BL and HL. Therefore the aim
of our study was to evaluate the expression of LMO2 in a
series of DLBCL, BL and HL speciﬁcally to determine its util-
ity in discriminating B cell lymphoma of GC origin from those
of the non-GC origin and then correlate its expression with dif-
ferent clinicopathological parameters.
Material and methods
Tissue samples
The cases were consecutively retrieved from the surgical
pathology ﬁles of the Suez Canal University hospital during
the period from January 2003 to December 2009. The study
included 68 lymphoma specimens divided into 35 DLBCL,
23 HL and 10 BL. Additional seven normal lymph node tissue
specimens were included. The specimens selected for this study
were based on the availability of complete clinical data and the
possibility of retrieving parafﬁn blocks from the diagnostic
biopsy samples. Cases of DLBCL were classiﬁed according
to the WHO classiﬁcation [12] into centroblastic when more
than 90% of the cells were centroblasts, centroblasticpolymorph when the proportion of immunoblasts ranged from
10% to 90%, and immunoblastic when more than 90% of tu-
mor cells were immunoblasts.
Formalin-ﬁxed, parafﬁn-embedded samples for LMO2
immunohistochemical staining
Hematoxylin and eosin-stained sections from each parafﬁn-
embedded, formalin-ﬁxed block were used to deﬁne diagnostic
areas and then representative sections of 5 lm were cut from
each parafﬁn block and stained with LMO2 monoclonal
antibody. Then the cases of DLBCL were stained with other
antibodies such as CD20, CD10, bcl-6, MUM1, bcl-2, and
MIB1 for their classiﬁcation. The antibodies, their sources,
clones, antigen retrieval buffer and dilutions are illustrated in
(Table 1).
All of the slides were deparafﬁnized using xylene and then
rehydrated in decreasing concentrations of ethanol. Antigen
retrieval (AR) using microwave heating (three times of
10 min) was performed after the inhibition of endogenous per-
oxidase activity (0.3 hydrogen peroxidase for 15 min). The
slides were incubated with the primary antibody at room tem-
perature, and then washed using phosphate buffered saline
(PBS) and then incubated with secondary antibody for
15 min followed by PBS wash. Finally the detection of bound
antibody was accomplished using the ABC reagent (ultra-
vision detection system, anti-polyvalent, ready to use, LAB
VISION, USA) for 20 min followed by PBS washes, 0.1%
solution of diaminobenzidine (DAB) was used for 5 min as a
chromogen and slides were counterstained with Mayer’s hema-
toxylin for 5–10 min. Negative controls were obtained by omit-
ting the primary antibody and reactive nodes were used as a
positive control for all antibodies.
A given lymphoma was judged positive when 20% positive
cells were immunostained by each antibody except MIB-1, the
percentage of positive cells for MIB-1 was estimated. The
number of MIB-1 positive cells and all tumor cells were deter-
mined by an actual count in areas (2.5 mm2) counted at high
power ﬁeld (400·), background of small lymphocytes and star-
ry sky macrophages were excluded, a mean of three areas in
each case was taken as the MIB-1 index and then the cases
classiﬁed into two groups with a cutoff point of 50% [13].
For LMO2 expression, The mean percentage of positive tumor
cells was determined in at least 10 ﬁelds at 400-fold magniﬁca-
tion and assigned one of the following four categories: 0,
<30%; 1, 30–<50%; 2, 50–<75%; 3, >75%. Cases were
considered positive if 30% or more of the tumor cells were
nuclear stained with an antibody then positive staining inten-
sity was scored into three categories, weak (1+), moderate
(2+) and strong (3+) [11]. Immunoperoxidase results for
CD10, bcl-6, and MUM1 were used to subclassify the cases
of DLBCL (Diagram 1). Cases were subdivided into GC like
B cells and NGC (ABC or type 3), based on the positivity
for CD10, bcl-6 and Mum-1. A case was considered of GC like
B cell origin if Mum-1 was negative and CD10 alone or both
CD10 and bcl-6 were positive [14–16]. ABC was considered
when cells were only positive for Mum-1 and type 3 when a
case was negative for CD10 but double positive or negative
for both bcl-6 and Mum-1.
A CD20 stain was performed to evaluate each section for
involvement of tumor, and each slide was evaluated indepen-
dently by two pathologists for the percentage of tumor cells
Table 1 Antibodies used for immunohistochemical stains.
Antibody Clone Source ARa Dilution Staining
CD20 L26 Dako Citrate 30 1:200 Membranous
CD10 270 Novocastra Citrate 60 1:20 Membranous
Bcl-2 124 Dako EDTA 30 1:50 Membranous
Bcl-6 BG-B6P Dako EDTA 60 1:20 Nuclear
MUM1 Polyclonal Dako EDTA 30 1:10 Nuclear
MIB-1 Monoclonal Dako EDTA 30 1:75 Nuclear
LMO2 1A9-1 Dako EDTA 60 1:150 Nuclear
Citrate 30 indicates 30 min at 95 C in citrate (10 mM, pH 6.0); citrate 60 indicates 60 min at 95 C in citrate (10 mM, pH 6.0).
EDTA 30 indicates 30 min at 95 C in EDTA (ethylene diamine tetra acetic acid; 1 mM, pH 8.0), EDTA 60 indicates 60 min at 95 C in EDTA
(1 mM, pH 8.0).
a AR (antigen retrieval).
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Disagreements were resolved by joint review on a multihead
microscope.
Statistical analysis
Either the v2 test or Fisher’s exact test was used as appropriate
to determine differences between variables. P value 60.05 was
considered statistically signiﬁcant, both ABC and type 3 were
grouped together as non-GC phenotype since the type 3 group
has similar outcome as that of the ABC group [17].
Results
Demographic data of the studied lymphoma cases
As shown in Table 2 a total of 35 cases of DLBCL were stud-
ied, the patients included 20 men and 15 women with a male to
female ratio of 1.3:1 with a median age of 47.3 years (range,
12–76), 30 cases (85.7%) were nodal and ﬁve cases (14.3%)
were extranodal. The cases were classiﬁed according to the
WHO classiﬁcation into centroblastic (20%), centroblastic
polymorph (71.4%) and immunoblastic (8.6%). Regarding
the stage most cases 19/35 (54.3%) were stage I and only three
cases (6.6%) were stage IV.
A total of 10 patients of BL were studied, including seven
men and three women with a male to female ratio of (2.3:1),
median age of 25 years (range 5–42 years). Most of the cases
are extranodal (one ovary, one colon, one omentum, one
ileum, two jejunum and the rest four cases were nodal.
Regarding HL the studied cases were 23 cases classiﬁed into
cHL 15/23 (65.2%) and NLPHL 8/23 (34.8%), the male to
female ratio was 2.6:1 with median age of 25.0. The cervical
lymph node is the most common site 18/23 (78.3%) and the
other sites represent 5/23 (21.7%).                 GCB             +         Non-GC  
         + 
CD10                    +        MUM1 
            _      BCL-6
  _                          _         
     GCB
Non-GC     
Diagram 1 The immunohistochemical classiﬁcation of DLBCL.LMO2 expression in normal control group
In all seven studied specimens of normal control lymph node,
LMO2 staining was positive with nuclear staining and the
staining intensity in all cases were weak (+). The positive
staining was restricted to the germinal center zones and there
was no staining in other zones including the mantle, marginal
or T cell zones.LMO2 expression in different studied cases of lymphomas
The results of immunohistochemical studies on 68 lymphoma
cases were summarized in Table 3. Hodgkin’s lymphoma
(HL) showed the highest percentage of cases expressing
LMO2 with 100% of both classic HL (cHL) and nodular lym-
phocytic predominant HL (NLPHL) demonstrating positive
staining in the neoplastic cells only (Fig. 1). The intensity of
staining was strongly positive (3+) in 69.7% (16/23), in
(cHL) 10 cases out of 15 (66.7%) were strongly positive com-
pared with six out of eight cases (75.0%) in (NLPHL).
Out of the 10 cases of studied Burkitt lymphoma (BL), nine
cases were positive for LMO2 in a percentage of (90%); most
of the positive cases 7/9 (77.8%) were strongly positive (3+) as
shown in (Fig. 2).
In DLBCL, cases were subdivided into germinal center
(GC) like B cells, activated B cells (ABC) or type 3, based
on the positivity for CD10, bcl-6 and Mum-1. According to
this classiﬁcation; in our study 20 cases were classiﬁed as
(GC), all of them were Mum1 negative, eight cases were double
positive CD10 and Bcl-6 and 12 cases were CD10 positive
alone. The 15 cases of the NGC group were divided into
ABC (5 cases) which are all positive for Mum-1 and type 3
(10 cases) as ﬁve cases CD10 were negative, two cases were
double positive for Bcl-6 and MUM-1,the remaining three
cases were double negative for Bcl-6 and Mum-1.
Regarding the LMO2 expression in DLBCL 20/35 (57.1%)
were positive. All cases of GC DLBCL 20/20 (100%) were
positive and all cases of NGC were negative (Table 4). Most
of the positive cases 15/20 (75%) were strongly positive (3+)
as shown in (Fig. 3) compared with 2/20 (25.0%) of moderate
staining (2+).
When we grouped all studied cases of lymphomas together,
most cases 38/52 (73.1%) were strongly LMO2 positive com-
pared by weak stain in all positive cases of normal lymph nodes,
this difference in staining intensity between normal and lympho-
mas were statistically signiﬁcant (P= 0.01) data not shown.
Table 3 LMO2 expression in studied lymphomas.
Lymphomas Total (68) LMO2 expression
Positivea Negativea
1+ 2+ 3+ Total (%)
DLBCLb 35 0 5 15 20 (57.1) 15
cHLb 15 1 4 10 15 (100) 0
NLPHLb 8 1 1 6 8 (100) 0
BLb 10 1 1 7 9 (90) 1
a Positive: 30% or more of tumor cells showed nuclear staining of any intensity, (1+) weak, (2+) moderate, (3+) strong staining intensity.
Negative less than 30% of tumor cells positive.
b DLBCL (diffuse large B cell lymphoma); cHL (classical Hodgkin’s lymphoma); NLPHL (nodular lymphocytic predominant Hodgkin’s
lymphoma); BL (Burkett lymphoma).
Figure 1 LMO2 expression in nodular lymphocytic predominant
Hodgkin lymphoma with strong immunostaining (3+) in neo-
plastic cells cells (DAB · 200).
Figure 2 LMO2 immunostaining in Burkett lymphoma with
strong (3+) staining (DAB · 200).
Table 2 Clinical characteristics and correlation with LMO2 expression of DLBCL studied cases.
Clinical character Number (%) LMO2 positive P value
Age
<47 12 (34.3%) 10 (83.3%) NSa
P47 23 (65.7%) 10 (43.4%)
Sex
Male 20 (57.1%) 12 (60%) NSa
Female 15 (42.9%) 8 (53.3%)
Stage
I 19 (54.3%) 13 (68.4%) NSa
II 5 (14.3%) 2 (40%)
III 8 (22.8%) 4 (50%)
IV 3 (6.6%) 1 (33.3%)
Site
Nodal 30 (85.7%) 17 (56.7%) NSa
Extranodal 5 (14.3%) 3 (60%)
Histological subtype
Centroblastic 7 (20%) 3 (42.9%) NSa
Centroblastic-polymorph 25 (71.4%) 16 (64%)
Immunoblastic 3 (8.6%) 1 (33.3%)
Immunophenotyping
GCb 20 (57.1%) 20 (100%) Sa 0.03
NGC 15 (42.9%) 0 (0%)
ABC 5 (14.3%) 0 (0%)
Type 3 10 (28.6%) 0 (0%)
a NS (not signiﬁcant P value more than 0.05), S (signiﬁcant P value less than 0.05.
b GCB (germinal center like B cells); NGC (non-germinal center); ABC (activated B cells).
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Figure 3 LMO2 expression in DLBCL with strong immuno-
staining (3+) in lymphoma cells (DAB · 200).
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MIB1 immunostaining
As shown in Table 5 LMO2 was expressed in (100%) in GCB
cases; in contrast it was negative in all studied cases of NGC.
Statistically signiﬁcant P= 0.03. This indicates that we can
use this marker to differentiate between these two groups.
In addition, MIB-1 was signiﬁcantly expressed in NGC
phenotype which indicates the inverse relationship between
LMO-2 expression and MIB-1 expression (P= 0.03). Regard-
ing bcl2 there is insigniﬁcant difference p= 0.017.
Correlation between LMO2 expression and clinicopathological
characters of DLBCL studied cases
As shown in Table 2 there is no signiﬁcant relation between
LMO2 expression and age, sex, stage, nodal or extranodal tu-
mor site, Histological subtype regarding centroblastic, cen-
troblastic polymorph or immunoblastic. There is only
signiﬁcant difference in LMO2 expression regarding immuno-
phenotyping of GC versus NGC DLBCL. (p= 0.03).
Correlation between DLBCL and BL with bcl-6, bcl-2 and
MIB1 immunostaining
The bcl-2 was expressed in 1/10 (10%) and 15/35 (42.9%) in BL
and DLBCL respectively this difference was statistically insig-
niﬁcant. Regarding bcl-6, it was expressed in all ten cases of
BL compared with 10/35 (28.6%) of DLBCL but this difference
was statistically insigniﬁcant. MIB-1 index of BL and DLBCL
were distributed from 92% to 95% with a mean of 96% and
from 45% to 87% with a mean of 50% respectively. There
was statistically insigniﬁcant difference between them
p= 0.15 (Table 6).
Discussion
LMO2 plays an important role in angiogenesis and erythropoi-
esis and is required for deﬁnitive hematopoiesis during mouse
embryogenesis [18,19]. In hematopoietic cells it appears to act
as an intranuclear bridging molecule, orchestrating protein–
protein interactions in the formation of multiprotein com-
plexes that are necessary for the speciﬁcation of cell lineage
and differentiation [20]. LMO2 is very speciﬁc for hematopoi-
etic tissue which is conﬁrmed by Natkunam et al. [11] who
studied the expression of LMO2 protein in non-hematopoietic
normal and neoplastic tissue from each of the following
organs: adrenal, bladder, brain, breast, colon, kidney, liver,
lung, muscle (heart and skeletal), ovary, pancreas, prostate,
stomach, testis, thyroid, and uterus and no LMO2 stainingTable 4 LMO2 staining intensity in different subtypes of BLBCL.
IHC classiﬁcation Total N (%) LMO2 expres
Positive
1+
GCBa 20 0
NGCBa 15 0
a GCB (germinal center like B cells); NGC (non-germinal center).was detected in any non-hematopoietic tissue, with the excep-
tion of vascular endothelial cells.
However, despite these extensive investigations based on
the assessment of mRNA levels, the studies of LMO2 at the
protein level are very limited. In this paper we studied the
expression of LMO2 in routinely processed parafﬁn blocks
in normal and neoplastic human nodal tissues.
In this study; LMO2 protein was highly expressed in lym-
phocytes within the germinal center in normal lymph nodes;
the staining was localized to the nucleus. Mantle and marginal
zones are negative for staining. The interfollicular areas
showed LMO2 staining on endothelial cells and scattered
histiocytes which is in accordance with other literature [11].
We found that the expression of LMO2 is high in HL
(100%), while the cell of origin in HL was a mystery for many
years, it is now well recognized that these lymphomas are de-
rived from GCB cells in both cHL and NLPHL [21,22].
Although malignant cells of cHL show a characteristic down
regulation of B-cell surface markers while those in NLPHL
show preservation of these markers [23], but the antigen
PAX-5 was expressed by both types, interestingly our ﬁndings
indicate that LMO2 is consistently expressed in both subtypes
of HL but the intensity is more in cHL.
The germinal center provides a microenvironment in which
naı¨ve B cells proliferate and diversify their antigen receptors to
produce high-afﬁnity antibodies [24,25]. It is well recognized
that the dysregulation of these steps of normal B-cell ontogeny
plays an important role in the genesis of GC-derived B-cell
lymphomas [26]. In the studied cases of BL (90%) were posi-
tive for LMO2 which is consistent with other results which
documented that LMO2 is highly expressed at the messenger
RNA and protein levels in normal GCB and in many B-cell
lymphomas that are thought to be of GCB origin, such as fol-
licular lymphoma and Burkitt lymphoma [11,27].sion
Negative
2+ 3+ Total
5 15 20 0
0 0 0 0
Table 5 Correlation between DLBCL subgroups and LMO2,
Bcl-2 and MIB-1 immunostaining.
Subtype GCBa
N (%)
NCGa
N (%)
P value
LMO2
Positive 20 (100) 0 (0) 0.03
Negative 0 (0) 15 (100)
Bcl-2
Positive 0 (0) 13 (86.7) NSa
Negative 20 (100) 2 (13.3)
MIB-1
>50% 18 (90) 1 (6.7) 0.03
650% 2 (10) 14 (93.3)
a GCB (germinal center like B cells); NGC (non-germinal center);
NS (not signiﬁcant).
Table 6 Correlation between expression of bcl-6, bcl-2 and
MIB-1 in DLBCL and BL.
Subtype DLBCLa
N (%)
BLa
N (%)
P value
Bcl-6
Positive 10 (28.6) 10 (100) NSa
Negative 25 (71.4) 0 (0)
Bcl-2
Positive 15 (42.9) 1 (10) NSa
Negative 20 (57.1) 9 (90)
MIB-1
>50% 18 (51.4) 8 (80) NSa
650% 17 (48.6) 2 (20)
a DLBCL (diffuse large B cell lymphoma), BL (Burkett lym-
phoma), NS (not signiﬁcant P value more than 0.05).
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was (57.1%) which is similar to the reported rate of 50–55%
[11,28]. DLBCL with a gene expression proﬁle similar to that
of GCB cells exhibits a more favorable clinical outcome [27]. Fi-
nally, LMO2 is of clinical relevance in DLBCL, since its expres-
sion level in DLBCL is a powerful predictor of patient survival,
probably in part because it identiﬁes cases of germinal-center
cell origin [29] and as showed in this study, it may be due to its
association with low expression of bcl-2, a known adverse prog-
nostic factor inDLBCL. In this study, we did not have chance to
study the survival effect of LMO2 expression which is very
important so we must include this in another study.
In this study LMO2 was expressed in GC DLBCL and not
expressed in NGC subtype so among DLBCL, LMO2 tended
to be expressed in cases assigned by phenotyping to the GC cat-
egories and it can therefore be added to the panel ofmarkers that
pathologists may use to subcategorize lymphomas. On the other
hand, the nuclear staining associated with LMO2 protein offers
easier interpretation Thus, LMO2 could be extremely valuable
in the diagnosis of small tissue samples and needle biopsies. Also
the staining intensity of normal lymph nodes is weak compared
with strong intensity in lymphomas; a point can be considered in
differentiating normal versus lymphomas.Conclusions
Our results throw light on the expression of LMO2 in normal
and neoplastic lymphoid tissue, its positive expression in GC
DLBCL can be used in distinguishing a spectrum of lympho-
mas of GC derived B-cell lymphoma from those that are not
of GC origin. The prognostic impact of LMO2 on lymphoma
patients should be emphasized before the application of this
marker in routine clinical practice.Acknowledgment
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